Edgewise Therapeutics Inc (EWTX)

Apr 10, 2025, 6:56 AM EDT - 13 days ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP GNFT

Apr 2, 2025, 4:54 PM EDT - 21 days ago

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

Apr 2, 2025, 12:27 PM EDT - 21 days ago

Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

Apr 2, 2025, 6:22 AM EDT - 21 days ago

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Apr 2, 2025, 6:00 AM EDT - 21 days ago

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

Mar 26, 2025, 4:45 PM EDT - 4 weeks ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Mar 11, 2025, 8:00 AM EDT - 6 weeks ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Mar 10, 2025, 1:36 PM EDT - 6 weeks ago

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Mar 4, 2025, 8:00 AM EST - 7 weeks ago

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

Mar 3, 2025, 8:00 AM EST - 7 weeks ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Jan 22, 2025, 8:00 AM EST - 3 months ago

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Jan 13, 2025, 8:00 AM EST - 3 months ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Jan 7, 2025, 8:00 AM EST - 3 months ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Dec 31, 2024, 2:09 PM EST - 4 months ago

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Dec 16, 2024, 11:56 AM EST - 4 months ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Dec 16, 2024, 6:00 AM EST - 4 months ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Dec 5, 2024, 2:32 PM EST - 4 months ago

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Nov 26, 2024, 6:00 AM EST - 5 months ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Nov 7, 2024, 8:00 AM EST - 5 months ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 1, 2024, 8:00 AM EDT - 7 months ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Sep 30, 2024, 12:12 PM EDT - 7 months ago

Analysts Think There's Still Time To Get In On Edgewise

Sep 25, 2024, 11:50 AM EDT - 7 months ago

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Sep 19, 2024, 10:19 AM EDT - 7 months ago

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment

Sep 19, 2024, 7:00 AM EDT - 7 months ago

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Sep 17, 2024, 4:01 PM EDT - 7 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Aug 8, 2024, 8:00 AM EDT - 9 months ago

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 5, 2024, 2:38 PM EDT - 9 months ago

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

May 10, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 7, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

May 6, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

Mar 5, 2024, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

Feb 28, 2024, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Feb 22, 2024, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 13, 2024, 8:00 AM EST - 1 year ago

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

Jan 19, 2024, 8:37 AM EST - 1 year ago

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Jan 9, 2024, 8:39 AM EST - 1 year ago

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 28, 2023, 3:00 PM EST - 1 year ago

Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing

Dec 26, 2023, 5:21 PM EST - 1 year ago

Wedbush's Laura Chico talks biotech investing in 2024

IBB NBIX VRDN XBI

Dec 19, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

Dec 18, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community

Nov 30, 2023, 8:00 AM EST - 1 year ago

Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

Nov 9, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 8, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Edgewise to Present Data on EDG-7500 at the American Heart Association's Scientific Sessions 2023

Oct 26, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)